CO2021007647A2 - Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos - Google Patents
Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismosInfo
- Publication number
- CO2021007647A2 CO2021007647A2 CONC2021/0007647A CO2021007647A CO2021007647A2 CO 2021007647 A2 CO2021007647 A2 CO 2021007647A2 CO 2021007647 A CO2021007647 A CO 2021007647A CO 2021007647 A2 CO2021007647 A2 CO 2021007647A2
- Authority
- CO
- Colombia
- Prior art keywords
- nanoemulsification
- production methods
- cannabis oil
- oil powder
- powder formulated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL261132A IL261132A (en) | 2018-08-13 | 2018-08-13 | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
| PCT/IL2019/050268 WO2020035850A1 (en) | 2018-08-13 | 2019-03-11 | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021007647A2 true CO2021007647A2 (es) | 2021-08-30 |
Family
ID=63998426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0007647A CO2021007647A2 (es) | 2018-08-13 | 2021-06-10 | Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11712430B2 (https=) |
| EP (1) | EP3716946A1 (https=) |
| JP (1) | JP2021535935A (https=) |
| CN (1) | CN113473965A (https=) |
| AU (1) | AU2019322212B2 (https=) |
| BR (1) | BR112021009869A2 (https=) |
| CO (1) | CO2021007647A2 (https=) |
| IL (2) | IL261132A (https=) |
| WO (1) | WO2020035850A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020220141A1 (en) * | 2019-05-02 | 2020-11-05 | Betterlife Pharma Inc. | Cannabinoid stock transdermal formulations |
| US10780075B1 (en) | 2019-07-31 | 2020-09-22 | Etain IP, LLC | Water soluble cannabis composition |
| AU2020330527A1 (en) * | 2019-08-12 | 2022-02-24 | Tenshi Kaizen Private Limited | Cannabidiol orally disintegrating tablets |
| CA3166084C (en) | 2020-07-29 | 2025-06-10 | Karnak Technologies, Llc | Oral compositions of beneficial lipophilic, nutriceutical, and edible oil food supplements |
| AU2021317264A1 (en) * | 2020-07-29 | 2022-09-22 | Karnak Technologies, Llc | Improved formulations of lipophilic subtances for cosmetic uses |
| US20230270678A1 (en) * | 2020-07-29 | 2023-08-31 | Karnak Technologies, Llc | Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives |
| EP4196112A4 (en) * | 2020-08-14 | 2024-10-16 | Capheads LLC | CANNABIS-DERIVED RESIN DOSING CAPSULE AND METHOD FOR THE PRODUCTION THEREOF |
| CA3114085A1 (en) * | 2021-04-05 | 2022-10-05 | MEC11S Inc. | Composition comprising cannabis extracts and method of manufacturing same |
| JP2023010676A (ja) * | 2021-07-09 | 2023-01-20 | 株式会社東洋新薬 | 固形組成物 |
| US20240415854A1 (en) | 2023-06-16 | 2024-12-19 | Miles J. Terry | Process for creating a cannabinoid pico-emulsion with antibiotic properties and the resulting pico-emulsion |
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
| WO2026037496A1 (en) * | 2024-08-14 | 2026-02-19 | Tetra Pharm Technologies | A self-emulsifying solid composition comprising a cannabinoid |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130102591A1 (en) * | 2010-01-26 | 2013-04-25 | Andrew Lurie Salzman | Compositions and methods for prevention and treatment of pulmonary hypertension |
| US8629177B2 (en) * | 2010-08-24 | 2014-01-14 | Aphios Corporation | Nanoencapsulated delta-9-tetrahydrocannabinol |
| DK2804587T3 (da) | 2012-01-19 | 2019-08-12 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed |
| WO2013172999A1 (en) | 2012-05-16 | 2013-11-21 | Mewa Singh | Pharmaceutical compositions for the delivery of substantially water-insoluble drugs |
| US10213391B2 (en) | 2014-05-06 | 2019-02-26 | Mewa Singh | Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation |
| US20160058866A1 (en) | 2014-09-02 | 2016-03-03 | Ronald D. Sekura | Alternative solutions for the administration of cannabis derived botanical products |
| US9629886B2 (en) | 2015-02-24 | 2017-04-25 | Ers Holdings, Llc | Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil |
| AU2016231788A1 (en) | 2015-03-19 | 2017-10-12 | One World Cannabis Ltd | Preparations of cannabis emulsions and methods thereof |
| CA2986268C (en) * | 2015-05-28 | 2024-01-02 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| BR102015024165A2 (pt) * | 2015-09-18 | 2017-03-28 | Prati Donaduzzi & Cia Ltda | composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso |
| EP3368014B1 (en) * | 2015-10-26 | 2023-10-04 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | Novel cannabinoid formulations |
| EP3442522A4 (en) | 2016-04-15 | 2020-01-01 | SRE Wellness, Inc. | METHOD FOR PRODUCING HYDROPHILIZED CANNABI OIL USING EMULSIFIERS AND RELATED CANNABINOID COMPOSITIONS |
| EP3558297A1 (en) * | 2016-12-20 | 2019-10-30 | Tilray, Inc. | Novel cannabinoid compositions and methods of treating pediatric epilepsy |
| CO2017007962A1 (es) * | 2017-08-04 | 2018-04-19 | Alsec Alimentos Secos S A S | Nanoparticulas oleosas de cannabis microencapsuladas en polvo |
-
2018
- 2018-08-13 IL IL261132A patent/IL261132A/en unknown
-
2019
- 2019-03-11 CN CN201980067584.5A patent/CN113473965A/zh active Pending
- 2019-03-11 US US16/958,341 patent/US11712430B2/en active Active
- 2019-03-11 EP EP19714807.5A patent/EP3716946A1/en not_active Withdrawn
- 2019-03-11 AU AU2019322212A patent/AU2019322212B2/en active Active
- 2019-03-11 BR BR112021009869A patent/BR112021009869A2/pt not_active Application Discontinuation
- 2019-03-11 WO PCT/IL2019/050268 patent/WO2020035850A1/en not_active Ceased
- 2019-03-11 JP JP2021547984A patent/JP2021535935A/ja active Pending
-
2020
- 2020-06-17 IL IL275430A patent/IL275430A/en unknown
-
2021
- 2021-06-10 CO CONC2021/0007647A patent/CO2021007647A2/es unknown
-
2023
- 2023-06-14 US US18/209,954 patent/US20230321031A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210059975A1 (en) | 2021-03-04 |
| CA3086887A1 (en) | 2020-02-20 |
| AU2019322212B2 (en) | 2022-09-29 |
| WO2020035850A1 (en) | 2020-02-20 |
| IL275430A (en) | 2020-08-31 |
| EP3716946A1 (en) | 2020-10-07 |
| IL261132A (en) | 2018-11-04 |
| US20230321031A1 (en) | 2023-10-12 |
| JP2021535935A (ja) | 2021-12-23 |
| US11712430B2 (en) | 2023-08-01 |
| AU2019322212A1 (en) | 2021-04-08 |
| BR112021009869A2 (pt) | 2022-05-17 |
| CN113473965A (zh) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021007647A2 (es) | Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos | |
| CR20210483A (es) | Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos | |
| CL2017001893A1 (es) | Uso de prg4 como agente antiinflamatorio | |
| CL2019003636A1 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson. | |
| CL2018003432A1 (es) | Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales. | |
| PE20200726A1 (es) | Composicion de cannabis | |
| MX2018013472A (es) | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. | |
| MX388693B (es) | Composiciones de nanoparticulas para terapia sostenida. | |
| MX370963B (es) | Composiciones para el cuidado personal. | |
| WO2015089419A3 (en) | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components | |
| EP4653048A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| PE20200338A1 (es) | Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil | |
| CL2016002276A1 (es) | Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad | |
| MX2019009783A (es) | Metodo para fabricar una barra que comprende antitranspirante. | |
| AR085527A1 (es) | Una composicon farmaceutica para tratar una enfermedad en la cavidad oral que comprende rebamipida | |
| MX373742B (es) | Composiciones para el cuidado personal que comprenden partículas de superficie modificada y silicona funcionalizada no volátil. | |
| MX2017004998A (es) | Composicion que contiene un extracto o fraccion de una planta del genero justicia. | |
| MX2020010284A (es) | Método y composición para el tratamiento de los trastornos del snc. | |
| HK1217092A1 (zh) | 治疗性化合物及其用途 | |
| MX2019007614A (es) | Nanoparticulas para su uso para tratar un trastorno neuronal. | |
| AR075686A1 (es) | Nanoparticulas de policosanol | |
| CO2017007962A1 (es) | Nanoparticulas oleosas de cannabis microencapsuladas en polvo | |
| MX375799B (es) | Preparación de absorbedores de uv de tamaño nanométrico. | |
| IT201700067430A1 (it) | Nanoparticelle quali veicoli di rilascio di principi attivi e metodi per la loro produzione | |
| ECSP19018116A (es) | 1arilnaftiridin3carboxamidas 7sustituidas y su uso |